It would help if the drug worked consistently, rather than just helping a few patients a lot and many patients not at all.
It's my belief that most of the people who are approved for Ampligen are living in conditions of extreme toxicity, which is what's causing them to be experiencing the high levels of inflammation that cause pathogens to thrive.
Even if the Ampligen modulates this somewhat, reducing the inflammation and allowing their systems to target the bugs better, it may not be enough to overcome the handicap of the inflammatory toxins.
What we need is a trial where only people who are living in "okay" conditions (not extreme avoidance, just a decently non-moldy house in a place without horrific levels of outdoor toxins) use the drug. If they all improved a lot, it would suggest a strategy for how we might better use the drug and (thus) get it approved.
Best, Lisa